ASCO GU 2019 Press Releases

Viewing 1-8 of 8 articles

ASCO GU 2019: Phase 3 Study of Androgen Deprivation Therapy with Enzalutamide or Placebo in Metastatic Hormone-Sensitive Prostate Cancer: The ARCHES Trial

MDxHealth Announces Presentation of Positive Data for SelectMDx and ConfirmMDx in Prostate Cancer Diagnosis

ARAMIS: Efficacy and Safety of Darolutamide in nmCRPC | ASCO GU 2019

Phase 3 ARCHES Trial Shows XTANDI® (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer

Phase II Trial Shows Novel, Radiolabeled PSMA-Targeted Treatment Provides High Response Rates in Men with Metastatic Prostate Cancer

African-American Men with Advanced Prostate Cancer Live Longer Compared With White Men When Treated with Newer Hormone Therapies

Pembrolizumab Plus Axitinib Extended Overall Survival and Progress-Free Survival Versus Current Standard Treatment for Advanced Kidney Cancer

Blue Earth Diagnostics Announces Axumin® (Fluciclovine F 18) LOCATE Study Presentation at Upcoming ASCO 2019 Genitourinary Cancers Symposium on Impact on Clinical Management of Recurrent Prostate Cancer

E-Newsletters

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.